valproic acid has been researched along with Dyslipidemias in 9 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with COC led to elevated fasting blood glucose, insulin, corticosterone, triglycerides (TG), TG/HDL-cholesterol ratio, insulin resistance (IR) and impaired glucose tolerance." | 7.83 | Improvement of oral contraceptive-induced glucose dysregulation and dyslipidemia by valproic acid is independent of circulating corticosterone. ( Kim, I; Olatunji, LA; Omolekulo, TE; Usman, TO, 2016) |
| " Ziprasidone may be a good alternative for patients with bipolar disorder experiencing a suboptimal response or intolerance to olanzapine in combination with a mood stabilizer because of its mood-stabilizing effect and minimal propensity for clinically significant body weight gain and metabolic disturbances." | 4.89 | The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study. ( Bahk, WM; Kim, MD; Kwon, YJ; Lee, HB; Lee, JG; Woo, YS; Yoon, BH, 2013) |
| "Treatment with COC led to elevated fasting blood glucose, insulin, corticosterone, triglycerides (TG), TG/HDL-cholesterol ratio, insulin resistance (IR) and impaired glucose tolerance." | 3.83 | Improvement of oral contraceptive-induced glucose dysregulation and dyslipidemia by valproic acid is independent of circulating corticosterone. ( Kim, I; Olatunji, LA; Omolekulo, TE; Usman, TO, 2016) |
| "Valproic acid has been shown to upregulate estrogen receptors (ERs) in breast and prostate cancer tissues." | 1.48 | Magnesium valproate ameliorates type 1 diabetes and cardiomyopathy in diabetic rats through estrogen receptors. ( Bhadada, S; Dudhrejiya, A; Patel, B; Rabadiya, S; Vaishnav, D, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Jutrić, D | 1 |
| Đikić, D | 1 |
| Boroš, A | 1 |
| Odeh, D | 1 |
| Drozdek, SD | 1 |
| Gračan, R | 1 |
| Dragičević, P | 1 |
| Crnić, I | 1 |
| Jurčević, IL | 1 |
| Rabadiya, S | 1 |
| Bhadada, S | 1 |
| Dudhrejiya, A | 1 |
| Vaishnav, D | 1 |
| Patel, B | 1 |
| Li, R | 1 |
| Qin, X | 1 |
| Liang, X | 1 |
| Liu, M | 1 |
| Zhang, X | 1 |
| Lee, HB | 1 |
| Yoon, BH | 1 |
| Kwon, YJ | 1 |
| Woo, YS | 1 |
| Lee, JG | 1 |
| Kim, MD | 1 |
| Bahk, WM | 1 |
| Olatunji, LA | 1 |
| Omolekulo, TE | 1 |
| Usman, TO | 1 |
| Kim, I | 1 |
| Chen, PS | 1 |
| Chang, HH | 1 |
| Huang, CC | 1 |
| Lee, CC | 1 |
| Lee, SY | 1 |
| Chen, SL | 1 |
| Huang, SY | 1 |
| Yang, YK | 1 |
| Lu, RB | 1 |
| Elmslie, JL | 1 |
| Porter, RJ | 1 |
| Joyce, PR | 1 |
| Hunt, PJ | 1 |
| Shand, BI | 1 |
| Scott, RS | 1 |
| Kenna, HA | 1 |
| Jiang, B | 1 |
| Rasgon, NL | 1 |
| Verrotti, A | 1 |
| Manco, R | 1 |
| Agostinelli, S | 1 |
| Coppola, G | 1 |
| Chiarelli, F | 1 |
2 reviews available for valproic acid and Dyslipidemias
| Article | Year |
|---|---|
The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Substitution; Drug Therapy, Com | 2013 |
Reproductive and metabolic abnormalities associated with bipolar disorder and its treatment.
Topics: Bipolar Disorder; Dyslipidemias; Endocrine System Diseases; Female; Humans; Hypogonadism; Hypothalam | 2009 |
7 other studies available for valproic acid and Dyslipidemias
| Article | Year |
|---|---|
Effects of naringin and valproate interaction on liver steatosis and dyslipidaemia parameters in male C57BL6 mice.
Topics: Animals; Cholesterol, LDL; Dyslipidemias; Fatty Liver; Flavanones; Liver; Male; Mice; Mice, Inbred C | 2022 |
Magnesium valproate ameliorates type 1 diabetes and cardiomyopathy in diabetic rats through estrogen receptors.
Topics: Animals; Cardiomegaly; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Cardiomy | 2018 |
Lipidomic characteristics and clinical findings of epileptic patients treated with valproic acid.
Topics: Anticonvulsants; Biomarkers; Dyslipidemias; Epilepsy; Female; Humans; Lipid Metabolism; Lipidomics; | 2019 |
Improvement of oral contraceptive-induced glucose dysregulation and dyslipidemia by valproic acid is independent of circulating corticosterone.
Topics: Animals; Anticonvulsants; Contraceptives, Oral, Combined; Corticosterone; Dyslipidemias; Female; Glu | 2016 |
A longitudinal study of the association between the GNB3 C825T polymorphism and metabolic disturbance in bipolar II patients treated with valproate.
Topics: Adult; Antimanic Agents; Biomarkers; Bipolar Disorder; Body Mass Index; Case-Control Studies; Dyslip | 2017 |
Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls.
Topics: Adiponectin; Adult; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Body Mass Index; Comorb | 2009 |
The metabolic syndrome in overweight epileptic patients treated with valproic acid.
Topics: Adolescent; Anticonvulsants; Body Mass Index; Cardiovascular Diseases; Child; Comorbidity; Dyslipide | 2010 |